Headlands Horizons LLC

1. Moderna TX, Inc. $10,028,964 3,146 payments
2. Pfizer Inc. $8,267,874 385 payments
3. Eli Lilly and Company $7,005,818 102 payments
4. AstraZeneca Pharmaceuticals LP $3,518,285 30 payments
5. Janssen Research & Development, LLC $1,916,594 197 payments
6. Amgen Inc. $728,464 2 payments
7. AstraZeneca UK Limited $639,840 6 payments
8. AbbVie, Inc. $615,396 150 payments
9. GlaxoSmithKline, LLC. $289,025 54 payments
10. Novavax Inc $212,763 45 payments

1. A Phase 3, Randomized, Observer-blind, Active-controlled, Case-drivenStudy to Investigate the Safety, Efficacy, and Immunogenicity of mRNA-1010 Candidate Seasonal Influenza Vaccine Compared with a Licensed Inactivated Seasonal Influenza Vaccine in Adults 50 Years of Age $1,966,623 41 payments
2. Phase 1, Randomized, Open label, Three-arm, Single Dose, Parallel Group Study to Compare AZD7442 (AZD8895 and AZD1061) Pharmacokinetic Exposure Following Intramuscular Administration as a Co-formulation versus Administration from Two Separate Vials of the Individual Monoclonal Antibodies in Adult Healthy Participants $1,954,217 7 payments
3. A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age $1,747,068 112 payments
4. A Randomized, Observer-Blind, Active-Controlled Phase 3 Study to Investigate the Safety, Immunogenicity, and Relative Vaccine Efficacy of mRNA-1283.222 Administered as a Booster Dose Compared With mRNA-1273.222 in Participants Aged 12 Years and Older for the Prevention of COVID-19 $1,684,318 987 payments
5. A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis $1,670,920 155 payments
6. A Phase 3 Randomized Observerblinded Study to Evaluate the Efficacy Safety Tolerability and Immunogenicity of A Modified Rna Vaccine Against Influenza Compared to Licensed Inactivated Influenza Vaccine in Healthy Adults 18 Years of Age Or Older $1,584,412 91 payments
7. A Study to Evaluate the Safety Tolerability and Immunogenicity of Modified Rna Vaccines Against Influenza in Healthy Adults $1,332,001 38 payments
8. A Phase 3 Randomized Observerblinded Study to Evaluate the Safety Tolerability and Immunogenicity of A Combined Modified Rna Vaccine Candidate Against Covid19 and Influenza in Healthy Individuals $1,300,908 45 payments
9. A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease $1,240,619 105 payments
10. A Phase 12 Randomized Doubleblind Trial of the Safety and Immunogenicity of A Multivalent Pneumococcal Conjugate Vaccine in Adults 18 Years of Age and Older $1,166,290 44 payments

1. Patient care $67,389 5 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.